ECHINOMYCIN (NSC-526417) IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A PHASE-II TRIAL OF THE GYNECOLOGIC ONCOLOGY GROUP

被引：23

作者：

MUSS, HB

BLESSING, JA

MALFETANO, J

机构：

[1] ALBANY MED CTR,DEPT OBSTET & GYNECOL,ALBANY,NY

[2] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103

[3] NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,GYNECOL ONCOL GRP,DEPT STAT,BUFFALO,NY 14263

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1990年 / 13卷 / 03期

关键词：

D O I：

10.1097/00000421-199006000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-eight evaluable patients with advanced or recurrent squamous-cell carcinoma of the cervix were treated with 1,500 μg/m2 of echinomycin every 4 weeks. All patients had prior chemotherapy. Two patients had partial responses (7% response, 95% confidence interval for response of 1 to 24%). The major toxicity was nausea and vomiting. Myelosuppression and other toxicity were modest. Echinomycin, at this dose and schedule, displays minimal activity in patients with squamous-cell carcinoma of the cervix who have had prior chemotherapy.

引用

页码：191 / 193

页数：3

共 50 条

[41] A Phase II Trial of Pyrazoloacridine (PZA) in Squamous Carcinoma of the Cervix – A Gynecologic Oncology Group Study
Steven C. Plaxe
John A. Blessing
Joseph A. Lucci
Jean A. Hurteau
Investigational New Drugs, 2001, 19 : 77 - 80
[42] Phase II trial of bevacizumab in the treatment of recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
Monk, B. J.
Sill, M. W.
Burger, R. A.
Gray, H. J.
Buekers, T. E.
Roman, L. D.
GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S21 - S22
[43] AMINOTHIADIAZOLE (NSC-4728) IN PATIENTS WITH ADVANCED NONSQUAMOUS CARCINOMA OF THE CERVIX - A PHASE-II STUDY OF THE GYNECOLOGIC ONCOLOGY GROUP
ASBURY, RF
BLESSING, JA
DISAIA, PJ
MALFETANO, J
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (05): : 375 - 377
[44] PALA (NSC-224131) IN ADVANCED-CARCINOMA OF THE CERVIX - A PHASE-II STUDY OF THE GYNECOLOGIC-ONCOLOGY-GROUP
MUSS, HB
BUNDY, B
DISAIA, PJ
STEHMAN, FB
BEECHAM, J
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1984, 7 (06): : 741 - 744
[45] Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group
Muggia, FM
Blessing, JA
McGehee, R
Monk, BJ
GYNECOLOGIC ONCOLOGY, 2004, 94 (02) : 483 - 487
[46] MITOXANTRONE FOR CARCINOMA OF THE ENDOMETRIUM - A PHASE-II TRIAL OF THE GYNECOLOGIC ONCOLOGY GROUP
MUSS, HB
BUNDY, BN
DISAIA, PJ
EHRLICH, CE
CANCER TREATMENT REPORTS, 1987, 71 (02): : 217 - 218
[47] PHASE-II STUDY OF VINBLASTINE IN PREVIOUSLY TREATED SQUAMOUS CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
SUTTON, GP
BLESSING, JA
BARNES, W
BALL, H
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (06): : 470 - 471
[48] Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
Monk, Bradley J.
Sill, Michael W.
Burger, Robert A.
Gray, Heidi J.
Buekers, Thomas E.
Roman, Lynda D.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) : 1069 - 1074
[49] PHASE-II TRIAL OF ETOPOSIDE IN THE MANAGEMENT OF ADVANCED OR RECURRENT NON-SQUAMOUS CELL-CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
SLAYTON, RE
BLESSING, JA
HOMESLEY, HD
CANCER TREATMENT REPORTS, 1984, 68 (12): : 1513 - 1514
[50] PHASE-II TRIAL OF ICRF-159 IN TREATMENT OF ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX
CONROY, J
BLESSING, J
LEWIS, G
MANGAN, C
HATCH, K
WILBANKS, G
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 423 - 423

← 1 2 3 4 5 →